Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Mesalazine controlled release oral pharmaceutical compositions|
|Abstract:||Controlled-release oral pharmaceutical compositions containing as active ingredient 5-amino-salicylic acid, comprising: a) an inner lipophilic matrix consisting of substances with a melting point below 90.degree. C. in which the active ingredient is at least partly inglobated; b) an outer hydrophilic matrix in which the lipophilic matrix is dispersed; c) optionally other excipients.|
|Inventor(s):||Villa; Roberto (Panama, PA), Pedrani; Massimo (Panama, PA), Ajani; Mauro (Panama, PA), Fossati; Lorenzo (Panama, PA)|
|Assignee:||Cosmo S.p.A. (Milan, IT)|
1. Controlled-release oral pharmaceutical compositions containing as an active ingredient 5-amino-salicylic acid, comprising: a) an inner lipophilic matrix consisting of
substances selected from the group consisting of unsaturated and/or hydrogenated fatty acid, salts, esters or amides thereof, fatty acid mono-, di- or triglycerids, waxes, ceramides, and cholesterol derivatives with melting points below 90.degree. C.,
and wherein the active ingredient is dispersed both in said the lipophilic matrix and in the hydrophilic matrix; b) an outer hydrophilic matrix wherein the lipophilic matrix is dispersed, and said outer hydrophilic matrix consists of compounds selected
from the group consisting of polymers or copolymers of acrylic or methacrylic acid, alkylvinyl polymers, hydroxyalkyl celluloses, carboxyalkyl celluloses, polysaccharides, dextrins, pectins, starches and derivatives, alginic acid, and natural or
synthetic gums; c) optionally other excipients; wherein the active ingredient is present in an amount of 80 to 95% by weight of the total composition, and wherein the active ingredient is dispersed both in the lipophilic matrix and in the hydrophilic
2. Compositions as claimed in claim 1, wherein 5-aminosalicylic acid is dispersed in a molten lipophilic matrix by kneading, extrusion and/or granulation.
3. Compositions as claimed in claim 1, in the form of tablets, capsules, mintablets.
4. A process for the preparation of the compositions of claim 1, which comprises: a) melt granulation of at least one portion of the active ingredient with the lipophilic excipients with melting point lower than 90.degree. C.; b) mixing the granules from step a) with the hydrophilic excipients and subsequent tabletting or compression.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.